 Evoke Pharma NASDAQ:EVOK was upgraded by equities research analysts at HC Wainwright from a neutral rating to a buy rating in a report released on Monday, Marketbeat.com reports. The brokerage currently has a 10.00 price target on the specialty pharmaceutical companys stock. HC Wainwrights price objective indicates a potential upside of 180.11 from the companys ... 